Research note from Redeye
February 9, 2018
(Non-regulatory)
Link to Redeye’s research note commenting Pledpharma’s press release from February 9.
News room
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment
February 9, 2018
(Non-regulatory)
Link to Redeye’s research note commenting Pledpharma’s press release from February 9.
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: info@egetis.com
